WHITEHOUSE STATION (dpa-AFX) - Merck reported data from the pivotal Phase III TAILOR study in patients from China, the first prospective trial to evaluate an anti-EGFR antibody in the first-line therapy of patients with RAS wild-type metastatic colorectal cancer. The company said the results demonstrated that Erbitux (cetuximab) plus FOLFOX statistically significantly improved outcomes, including progression-free survival, overall survival and best overall response rate, compared with FOLFOX alone. Compared with those receiving FOLFOX alone, patients in the study receiving Erbitux plus FOLFOX experienced: 31% decrease in risk of disease progression and 24% decrease in risk of death was achieved with addition of Erbitux to FOLFOX.
The company said the safety profile of Erbitux observed in TAILOR is similar to that seen in prior randomized clinical trials, with no unexpected safety findings.
Copyright RTT News/dpa-AFX